Composition for suppressing skin irritation

Abstract

To provide a composition for suppressing skin irritation. [Solution] A rash-suppressing composition characterized by containing one or more selected from the group consisting of low molecular weight hyaluronic acid, derivatives of low molecular weight hyaluronic acid, and salts thereof. In particular, the rash-suppressing composition used on delicate areas.

Description

Technical Field

[0001] The present invention relates to a composition for suppressing blisters. Specifically, it relates to a composition for suppressing blisters containing low-molecular-weight hyaluronic acid and the like.

Background Art

[0002] Conventionally, components that suppress various enzyme activities, which are factors for the onset, aggravation, etc. of blisters, and compositions containing such components have been proposed. For example, as a topical composition for the skin having a function of preventing blisters, a topical composition for the skin containing, as an active ingredient, plant extracts such as carrot, aloe, arrowroot, and celery having an action of suppressing the activities of protease, lipase, urease, etc. has been proposed (Patent Document 1). Further, as a topical composition for the skin having an effect of improving contact dermatitis, cosmetics, pharmaceuticals, etc. containing solvent extracts such as tormentil, button, and Japanese quince having an action of suppressing the activity of serine protease have been proposed (Patent Document 2). Further, as a topical composition for the skin having an effect of improving blisters, cosmetics, pharmaceuticals, etc. blended with extracts such as Japanese butterbur and common chickweed having an action of suppressing the activity of protease have been proposed (Patent Document 3). In addition, cosmetics, etc. blended with a specific ester compound having an action of suppressing the activity of lipase for the prevention of blisters have been proposed (Patent Document 4). Further, cosmetics, etc. blended with an extract of slenderleaf sedge having an action of suppressing the activity of urease as a blister-preventing component have been proposed (Patent Document 5).

[0003] However, conventionally, it has not been known at all that low-molecular-weight hyaluronic acid and the like have an action of suppressing enzyme activity and can suppress blisters.

Prior Art Documents

Patent Documents

[0004]

Patent Document 1

Patent Document 2

[0005] This invention has been made in view of the above circumstances, and its purpose is to provide a composition for suppressing skin irritation. [Means for solving the problem]

[0006] In view of the above circumstances, the inventors conducted extensive research and have newly discovered that skin irritation can be suppressed by using a specific type of hyaluronic acid.

[0007] In other words, the present invention provides the following [1] to [7]. [1] A composition for suppressing rashes, characterized by containing one or more selected from the group consisting of low molecular weight hyaluronic acid, derivatives of low molecular weight hyaluronic acid, and salts thereof. [2] A rash-inhibiting composition according to [1] that inhibits the activity of hydrolytic enzymes. [3] The rash-suppressing composition according to [2], wherein the hydrolytic enzyme is one or more selected from the group consisting of proteases, lipases, and ureases. [4] The rash-inhibiting composition according to [2] or [3], wherein the hydrolytic enzyme is a hydrolytic enzyme derived from a microorganism. [5] The rash-suppressing composition according to any one of [1] to [4], wherein the low molecular weight hyaluronic acid is hydrolyzed hyaluronic acid. [6] A composition for suppressing blisters according to any one of [1] to [5], which is for delicate parts. [7] A method for suppressing blisters by applying to the skin a composition containing at least one selected from the group consisting of low molecular weight hyaluronic acid, derivatives of low molecular weight hyaluronic acid, and salts thereof.

Advantages of the Invention

[0008] According to the present invention, a composition for suppressing blisters can be newly provided.

Brief Description of the Drawings

[0009] [Figure 1] It is a diagram showing the results of enzyme activity tests such as Examples and Comparative Examples.

Modes for Carrying Out the Invention

[0010] Embodiments of the present invention will be described in detail. However, the present invention is not limited to the following embodiments.

[0011] In this specification, when expressed as "X to Y" (X and Y are arbitrary numbers), unless otherwise specified, it includes the meaning of "X or more and Y or less" and also the meaning of "preferably greater than X" or "preferably less than Y". In this specification, "α and / or β" (α and β are arbitrary configurations or components) means three combinations: "only α", "only β", and "both α and β", unless otherwise specified. In this specification, for numerical ranges described stepwise, the upper limit value or lower limit value of a numerical range at a certain step can be arbitrarily combined with the upper limit value or lower limit value of a numerical range at another step. Also, in the numerical ranges described in this specification, the upper limit value or lower limit value of the numerical range can be replaced with the value shown in the Examples or Formulation Examples. <SD

[0012] <Composition for suppressing blisters> Conventionally, when the enzyme activities such as protease and lipase derived from resident bacteria and the like increase, for example, it is known that it can cause the onset of boils, the persistence or exacerbation of the symptoms of boils by weakening the skin barrier function. As a result of various studies on components capable of suppressing enzyme activity, the present inventors newly found that a specific hyaluronic acid has an effect of significantly suppressing enzyme activity, and thus reached the present invention.

[0013] As an embodiment of the present invention, in particular, a composition for preventing boils containing at least one selected from the group consisting of low-molecular-weight hyaluronic acid, derivatives of low-molecular-weight hyaluronic acid, and salts thereof (hereinafter sometimes referred to as "the present composition for preventing boils") is applied to the skin or the like, thereby exerting effects such as prevention of the onset of boils and treatment of the symptoms of boils.

[0014] Further, as an embodiment of the present invention, it is particularly preferable that it is a composition for preventing boils for delicate parts such as the genital area. That is, delicate parts are parts where the onset of boils and the exacerbation of the symptoms are particularly concerning. The delicate parts have a thinner stratum corneum and are more sensitive to stimulation than other parts of the body, and are likely to develop boils and the symptoms of boils are likely to exacerbate due to contact with physiological napkins, urine leakage sheets, underwear, etc., and contact with excreta such as feces and menstrual blood. Specifically, for example, urea in urine is decomposed into ammonia by urease produced by microorganisms in feces, the pH in feces increases due to the generated ammonia, and the enzyme activities of protease and lipase produced by bacteria present in delicate parts increase, thereby increasing the risk of the onset of boils and exacerbating the symptoms of boils. It is also known that a resident flora including Lactobacillus, Staphylococcus, Corynebacterium, Clostridium, Prevotella, Enterobacteriaceae, etc. is formed in delicate parts, and enzymes produced by such resident bacteria are also considered to be factors in the exacerbation of the symptoms (see, for example, JP-A-2018-088843). This rash-inhibiting composition is extremely useful in that it can prevent the onset of rashes in delicate areas such as the genitals, and alleviate the persistence and worsening of rash symptoms. The embodiments of the present invention will be described in more detail below.

[0015] [Low molecular weight hyaluronic acid, derivatives of low molecular weight hyaluronic acid, and salts thereof] This rash-suppressing composition is characterized by the use of one or more types of hyaluronic acid selected from the group consisting of low molecular weight hyaluronic acid, derivatives of low molecular weight hyaluronic acid, and salts thereof (these may be collectively referred to as "low molecular weight hyaluronic acid, etc."). These may be used individually or in combination of two or more types.

[0016] The origin of low-molecular-weight hyaluronic acid is not particularly limited; for example, it can be derived from chicken combs, microorganisms, pigs, sharks, and other sources.

[0017] There are no particular limitations on the method for producing low molecular weight hyaluronic acid. Examples include hydrolysis of high molecular weight hyaluronic acid in the presence of an acid or alkali such as hydrochloric acid, treatment using enzymes such as hyaluronidase, physical cutting by ultrasound or shearing, and fermentation by microorganisms.

[0018] The salts of low molecular weight hyaluronic acid are not particularly limited and can be any salt that is pharmaceutically, pharmacologically, or physiologically acceptable. Examples include salts with organic bases and salts with inorganic bases. Examples of salts with organic bases include salts with organic amines such as methylamine, triethylamine, triethanolamine, morpholine, piperazine, pyrrolidine, tripyridine, and picoline. Examples of salts with inorganic bases include ammonium salts; alkali metal salts such as sodium and potassium; alkaline earth metal salts such as calcium and magnesium; and salts with metals such as aluminum.

[0019] An example of low molecular weight hyaluronic acid is hyaluronic acid oligosaccharide. Hyaluronic acid oligosaccharide refers to a disaccharide or more that contains one unit of the basic structure (repeating unit) of GlcUA-GlcNAc, which is formed by the linkage of glucuronic acid (GlcUA) and N-acetylglucosamine (GlcNAc). Hyaluronic acid oligosaccharide preferably has one to ten repeating units of the basic structure linked together. Hyaluronic acid oligosaccharides are not limited to hyaluronic acid oligosaccharides, but examples include tetrasaccharide (HA4), hexasaccharide (HA6), octasaccharide (HA8), decasaccharide (HA10), and dodecasaccharide (HA12). For example, tetrasaccharide (HA4) hyaluronic acid oligosaccharide contains two units of the repeating unit of the basic structure.

[0020] Examples of derivatives of low molecular weight hyaluronic acid include derivatives obtained by etherification, esterification, amidation, acetylation, acetalization, etc., of the hydroxyl group, carboxyl group, etc., of low molecular weight hyaluronic acid. Examples include acetylated hyaluronic acid, sulfated hyaluronic acid, hydrophobized hydrolyzed hyaluronic acid (hydrolyzed alkyl hyaluronate, hydrolyzed glyceryl hyaluronate, etc.), cross-linked hyaluronic acid, carboxymethyl hyaluronic acid, alkylene glycol hyaluronic acid, silanol hyaluronic acid, cationized hyaluronic acid, and salts thereof.

[0021] The salts of low molecular weight hyaluronic acid derivatives are not particularly limited and can be any salt that is pharmaceutically, pharmacologically, or physiologically acceptable. Examples include salts with organic bases and salts with inorganic bases. Examples of salts with organic bases include salts with organic amines such as methylamine, triethylamine, triethanolamine, morpholine, piperazine, pyrrolidine, tripyridine, and picoline. Examples of salts with inorganic bases include ammonium salts; alkali metal salts such as sodium and potassium; alkaline earth metal salts such as calcium and magnesium; and salts with metals such as aluminum.

[0022] The weight-average molecular weight of low molecular weight hyaluronic acid, derivatives of low molecular weight hyaluronic acid, or salts thereof is less than 50,000. From the viewpoint of significantly achieving the effects of the present invention, the weight-average molecular weight is more preferably 40,000 or less, even more preferably 30,000 or less, particularly preferably 20,000 or less, and especially preferably 10,000 or less. Furthermore, the weight-average molecular weight of low molecular weight hyaluronic acid, derivatives of low molecular weight hyaluronic acid, or salts thereof is preferably 100 or more, more preferably 200 or more, and even more preferably 500 or more.

[0023] Note that the weight-average molecular weight mentioned above refers to the viscosity-average molecular weight, which can be determined by known measurement methods. Specifically, hyaluronic acid (dried material) is dissolved in a 0.2 M sodium chloride solution, and the intrinsic viscosity (η) at 30 ± 0°C is determined using an Ubbelohde viscometer, and Laurent's formula (η (intrinsic viscosity) = 3.6 × 10) is used. -4 ·M 0.78 The viscosity-average molecular weight is calculated based on (where M is the viscosity-average molecular weight). The intrinsic viscosity (η) is measured according to the General Test Methods for Viscosity Measurement, Method 1: Capillary Viscometer Method, of the 18th Revised Japanese Pharmacopoeia.

[0024] In preferred embodiments of the present invention, one or more selected from the group consisting of low molecular weight hyaluronic acid and its salts are preferred, and in particular, one or more selected from the group consisting of hydrolyzed hyaluronic acid and its salts are preferred. Hydrolyzed hyaluronic acid is hyaluronic acid that has been reduced in molecular weight to that of the raw material hyaluronic acid by acid treatment, alkali treatment, or enzymatic treatment with hyaluronic acid-degrading enzymes.

[0025] In addition, commercially available products can be used as low molecular weight hyaluronic acid, derivatives of low molecular weight hyaluronic acid, or salts thereof. Examples include Hyalo-Oligo (trade name, registered trademark) (manufactured by Kewpie Corporation; weight-average molecular weight 10,000 or less), Hyalozinc (trade name, registered trademark) (manufactured by Kewpie Corporation; weight-average molecular weight 10,000 or less), Hyaluronic Acid (SL) (trade name) (manufactured by FAP Japan Co., Ltd.; weight-average molecular weight 10,000 or less), Microhyaluronic Acid FCH (trade name) (manufactured by Kikkoman Biochemifa Co., Ltd.; weight-average molecular weight 5,000 or less), HAbooster (trade name, registered trademark) (manufactured by Kewpie Corporation; weight-average molecular weight 2,000), and HyalorePair (trade name, registered trademark) (manufactured by Kewpie Corporation; weight-average molecular weight 10,000 or less).

[0026] The content of low molecular weight hyaluronic acid, low molecular weight hyaluronic acid derivatives, or salts thereof in this rash-inhibiting composition can be appropriately set according to the type and amount of other components, dosage form, etc., and is not limited, but for example, it is preferably 0.0001% by mass or more, more preferably 0.0005% by mass or more, even more preferably 0.001% by mass or more, and even more preferably 0.005% by mass or more, based on the total amount (100% by mass) of the rash-inhibiting composition. Furthermore, the content of low molecular weight hyaluronic acid, low molecular weight hyaluronic acid derivatives, or salts thereof is preferably 5% by mass or less, more preferably 4% by mass or less, even more preferably 3% by mass or less, even more preferably 2% by mass or less, even more preferably 1% by mass or less, and even more preferably 0.5% by mass or less, based on the total amount (100% by mass) of the rash-inhibiting composition. Note that the above content refers to the total content of multiple types of low molecular weight hyaluronic acid, low molecular weight hyaluronic acid derivatives, and salts thereof.

[0027] As described above, applying a rash-suppressing composition containing one or more selected from the group consisting of low molecular weight hyaluronic acid, derivatives of low molecular weight hyaluronic acid, and salts thereof to the skin is effective in preventing and treating rashes. In a preferred embodiment of this rash-inhibiting composition, rashes are suppressed by inhibiting the activity of hydrolytic enzymes. Examples of enzymes whose activity is inhibited by the action of low molecular weight hyaluronic acid include hydrolytic enzymes. Examples of hydrolytic enzymes include microbial hydrolytic enzymes produced by microorganisms.

[0028] Examples of the aforementioned microorganisms include commensal bacteria such as skin flora, intestinal flora, and urinary tract flora. Specifically, these are not limited to the following, but examples include the genera Propionibacterium, Micrococcus, Corynebacterium, Staphylococcus, Lactobacillales, Clostridium, Alphaproteobacteria, Betaproteobacteria, and Gammaproteobacteria. Examples include genera such as mmaproteobacteria, Prevotella, Enterobacter, Bacteroides, Bifidobacterium, Clostridium, Escherichia, Candida, Streptomyces, Aspergillus, Penicillium, and Bacillus.

[0029] Examples of the hydrolytic enzyme include one or more selected from the group consisting of proteases, lipases, and ureases. Examples of the protease include serine protease, cysteine ​​protease, metalloprotease, threonine protease, aspartate protease, and glutamate protease. In preferred embodiments of the present invention, the rash-inhibiting composition preferably inhibits rash by inhibiting the activity of one or more enzymes selected from the group consisting of microbial-derived proteases, microbial-derived lipases, and microbial-derived ureases. Among these, it is preferable to inhibit the activity of microbial-derived proteases to suppress rash.

[0030] Furthermore, as an example of an embodiment of the present invention, it is preferable to suppress rashes by inhibiting the activity of serine proteases derived from microorganisms. Examples of serine proteases include trypsin, chymotrypsin, thrombin, plasmin, tissue-type plasminogen activator, urokinase-type plasminogen activator, and elastase.

[0031] [Other ingredients] In this rash-inhibiting composition, other components may be optionally added, as long as they do not impair the effects of the present invention. While not limited to the following, for example, bases or carriers, surfactants, thickeners, preservatives, pH adjusters, chelating agents, colorants, etc., may also be added. These can be used individually or in combination of two or more.

[0032] (Base or carrier) Examples of bases or carriers include lower alcohols such as ethanol and isopropanol; glycol ethers such as ethylene glycol monomethyl ether, ethylene glycol monoethyl ether, ethylene glycol monopropyl ether, diethylene glycol monomethyl ether, diethylene glycol monoethyl ether, diethylene glycol monopropyl ether, diethylene glycol monobutyl ether, propylene glycol monoethyl ether, propylene glycol monopropyl ether, dipropylene glycol monoethyl ether, and dipropylene glycol monopropyl ether; polyhydric alcohols such as polyethylene glycol, propylene glycol, 1,3-butylene glycol, glycerin, concentrated glycerin, isoprene glycol, diglycerin, dipropylene glycol, and sorbitol; hydrocarbons such as liquid paraffin, squalane, gelling hydrocarbons (such as Plastibase), ozokerite, and light liquid paraffin; methylpolysiloxane, cross-linked methylpolysiloxane, highly polymerized methylpolysiloxane, cyclic silicone, alkyl-modified silicone, and cross-linked alkyl Examples include silicone oils such as acrylic-modified silicones, amino-modified silicones, polyether-modified silicones, polyglycerin-modified silicones, cross-linked polyether-modified silicones, cross-linked alkyl polyether-modified silicones, silicone-alkyl chain-comodified polyether-modified silicones, silicone-alkyl chain-comodified polyglycerin-modified silicones, polyether-modified branched silicones, polyglycerin-modified branched silicones, acrylic silicones, phenyl-modified silicones, and silicone resins; oils and fats such as coconut oil, olive oil, rice bran oil, shea butter, rosehip oil, and almond oil; waxes such as jojoba oil, miu wax, candelilla wax, and lanolin; higher alcohols such as cetanol, cetostearyl alcohol, stearyl alcohol, behenyl alcohol, octyldodecanol, isostearyl alcohol, phytosterol, and cholesterol; dioxane; esters such as isopropyl myristate, octyldodecyl myristate, isopropyl palmitate, cetyl palmitate, isononyl isononanoate, and pentaerythritol tetra-2-ethylhexanoate.These can be used individually or in combination of two or more types.

[0033] The total content of the base or carrier can be appropriately set depending on the type and amount of other components, dosage form, etc., and is not limited, but from the viewpoint of significantly achieving the effects of the present invention, it is, for example, 45-90% by mass, 50-85% by mass, 55-80% by mass, 60-75% by mass, etc., relative to the total amount (100% by mass) of the rash-inhibiting composition.

[0034] (Surfactants) Examples of surfactants include anionic surfactants, nonionic surfactants, amphoteric surfactants, cationic surfactants, and naturally derived surfactants. These can be used individually or in combination of two or more.

[0035] The total amount of surfactant can be appropriately set depending on the type and amount of other components, dosage form, etc., and is not limited, but from the viewpoint of significantly achieving the effects of the present invention, it is, for example, 0.1 to 45% by mass, 0.1 to 20% by mass, or 0.1 to 10% by mass, relative to the total amount (100% by mass) of the rash-inhibiting composition. Alternatively, it may be 0.5 to 15% by mass, 1.0 to 10% by mass, or 1.5 to 8% by mass.

[0036] Examples of anionic surfactants include higher fatty acids such as palmitic acid, lauric acid, myristic acid, and stearic acid; higher fatty acid salts such as sodium palmitate, potassium laurate, sodium myristate, and potassium stearate; amino acid-based surfactants such as cocoyl glutamate, sodium cocoyl methyl taurate, cocoyl methyl taurate salt, cocoyl glycine salt, stearoyl glutamate, myristoyl glutamate, and lauroyl glutamate; alkyl sulfate esters such as sodium lauryl sulfate, triethanolamine lauryl sulfate, sodium laureth sulfate, sodium myristyl sulfate, sodium stearyl sulfate, sodium oleyl sulfate, and sodium cetyl sulfate; polyoxyethylene alkyl ether sulfates such as sodium polyoxyethylene lauryl ether sulfate and sodium polyoxyethylene myristyl ether sulfate; alkyl sulfosuccinates such as sodium dioctyl sulfosuccinate and disodium lauryl sulfosuccinate; and disodium polyoxyethylene lauryl sulfosuccinate. Examples include polyoxyethylene alkyl sulfosuccinates; monoalkyl phosphate salts such as sodium lauryl phosphate, sodium cetyl phosphate, and diethanolamine cetyl phosphate; polyoxyethylene alkyl ether phosphate salts such as sodium polyoxyethylene lauryl ether phosphate, sodium polyoxyethylene cetyl ether phosphate, sodium polyoxyethylene oleyl ether phosphate, sodium polyoxyethylene alkylphenyl ether phosphate, and triethanolamine polyoxyethylene alkylphenyl ether phosphate; and alkyl ether glycol acetates such as sodium lauryl glycol acetate (dodecane-1,2-diol acetate), potassium lauryl glycol acetate, sodium myristyl glycol acetate, potassium myristyl glycol acetate, sodium palmityl glycol acetate, potassium palmityl glycol acetate, sodium stearyl glycol acetate, potassium stearyl glycol acetate, sodium behenyl glycol acetate, and potassium behenyl glycol acetate.

[0037] The total content of anionic surfactants can be set appropriately depending on the type and amount of other components, dosage form, etc., and is not limited to these, but is typically 0.1-45% by mass, 0.5-40% by mass, 1-35% by mass, 2-30% by mass, or 2.5-25% by mass relative to the total amount (100% by mass) of the rash-inhibiting composition.

[0038] Examples of nonionic surfactants include sorbitan fatty acid esters such as sorbitan monoisostearate, sorbitan monolaurate, sorbitan monopalmitate, sorbitan monostearate, sorbitan diglycerol penta-2-ethylhexyl sorbitan, and sorbitan diglycerol tetra-2-ethylhexyl sorbitan; glycerin fatty acid esters such as lipophilic glyceryl monostearate, self-emulsifying glyceryl monostearate, and glyceryl malic monostearate; polyglyceryl monostearate, monoisos Polyglycerin fatty acid esters such as polyglyceryl thearate, polyglyceryl diisostearate, polyglyceryl monolaurate, polyglyceryl monooleate, and polyglyceryl monomyristate; propylene glycol fatty acid esters such as propylene glycol monostearate; ethylene glycol distearate, ethylene glycol monostearate, triethylene glycol distearate, polyethylene glycol monostearate (2 E.O.), polyethylene glycol monostearate (4 E.O.), polyethylene glycol monostearate (9 E.O.), polyethylene glycol monostearate (10 E.O.), polyethylene glycol monostearate (23 E.O.), polyethylene glycol monostearate (25 E.O.), polyethylene glycol monostearate (32 E.O.), polyethylene glycol monostearate (40 E.O.), polyethylene glycol monostearate (45 E.O.), polyethylene glycol monostearate (55 E.O.), polyethylene glycol monostearate Ethylene glycol fatty acid esters such as ethylene glycol (75 E.O.), polyethylene glycol monostearate (140 E.O.), polyethylene glycol distearate (140 E.O.), and polyethylene glycol distearate (250 E.O.); hydrogenated castor oil derivatives such as polyoxyethylene hydrogenated castor oil 40 (HCO-40), polyoxyethylene hydrogenated castor oil 50 (HCO-50), polyoxyethylene hydrogenated castor oil 60 (HCO-60), and polyoxyethylene hydrogenated castor oil 80 (HCO-80);Polyoxyethylene sorbitan fatty acid esters such as polyoxyethylene (20) sorbitan monolauryl acid (polysorbate 20), polyoxyethylene (20) sorbitan monostearate (polysorbate 60), polyoxyethylene (20) sorbitan monooleate (polysorbate 80), and polyoxyethylene (20) sorbitan isostearate; caprylic acid N-methylethanolamide, capric acid N-methylethanolamide, lauric acid N-methylethanolamide, lauric acid N-ethylethanolamide, lauric acid N- Methylpropanolamide, N-ethylpropanolamide laurate, N-methylisopropanolamide laurate, N-ethylisopropanolamide laurate, N-methylethanolamide myristate, N-methylethanolamide palmitate, N-methylethanolamide coconut oil fatty acid, N-ethylethanolamide coconut oil fatty acid, N-methylpropanolamide coconut oil fatty acid, N-ethylpropanolamide coconut oil fatty acid, N-methylisopropanolamide coconut oil fatty acid, N-ethylisopropanolamide coconut oil fatty acid Fatty acid alkanolamides such as oil fatty acid diethanolamide, palm kernel oil fatty acid N-methylethanolamide, palm kernel oil fatty acid N-ethylethanolamide, stearate N-methylethanolamide, stearate N-ethylethanolamide, oleate N-methylethanolamide, oleate N-ethylethanolamide; polyoxyethylene monococonut oil fatty acid glyceryl; glycerin alkyl ether; hexyl glucoside, capryl glucoside, nonyl glucoside, decyl glucoside, lauryl glucoside, myristyl glucoside, Examples include alkyl glucosides such as cetostearyl glucoside, hexadecyl glucoside, octadecyl glucoside, and coconut oil alkyl glucoside; polyoxyalkylene alkyl ethers such as polyoxyethylene lauryl ether, polyoxyethylene cetyl ether, polyoxyethylene stearyl ether, polyoxyethylene oleyl ether, and polyoxyethylene behenyl ether; and silicone-based surfactants such as lauryl PEG-9 polydimethylsiloxyethyl dimethicone and PEG-9 polydimethylsiloxyethyl dimethicone.

[0039] The total content of nonionic surfactants can be appropriately set depending on the type and amount of other components, dosage form, etc., and is not limited to these, but is typically 0.1-20% by mass, 0.5-15% by mass, 1-12% by mass, 2-10% by mass, or 2.5-8% by mass relative to the total amount (100% by mass) of the rash-inhibiting composition.

[0040] Examples of amphoteric surfactants include coconut oil fatty acid amidopropyl betaine, lauryl hydroxysulfobetaine, lauric acid amidopropyl betaine, 2-alkyl-N-carboxymethyl-N-hydroxyethylimidazolinium betaine, N-lauroyl-N'-carboxymethyl-N'-hydroxyethylethylenediamine sodium, lauramidopropyl hydroxybetaine, lauric acid amidopropyl dimethylamine oxide, and hydroxyalkyl(C12-14) hydroxyethyl sarcosine.

[0041] The total content of amphoteric surfactants can be set appropriately depending on the type and amount of other components, dosage form, etc., and is not limited to these, but is typically 0.1-20% by mass, 0.5-15% by mass, 1-12% by mass, 2-10% by mass, or 2.5-8% by mass relative to the total amount (100% by mass) of the rash-inhibiting composition.

[0042] Examples of cationic surfactants include stearyltrimethylammonium chloride, alkyltrimethylammonium chloride, cetyltrimethylammonium chloride, behenyltrimethylammonium chloride, behenyldimethylhydroxyethylammonium chloride, stearyldimethylbenzylammonium chloride, distearyldimethylammonium chloride, dicetylmethylammonium chloride, cetyltriethylammonium methyl sulfate, stearyltrimethylammonium bromide, and cetyltrimethylammonium bromide.

[0043] The total content of cationic surfactants can be appropriately set depending on the type and amount of other components, dosage form, etc., and is not limited to these, but is typically 0.1-5% by mass, 0.2-4% by mass, 0.3-3% by mass, or 0.4-2% by mass relative to the total amount (100% by mass) of the rash-inhibiting composition.

[0044] Examples of naturally derived surfactants include lecithin, hydrogenated lecithin, saponins, sodium surfactant, and bile acids.

[0045] The total amount of naturally derived surfactants can be set appropriately depending on the type and amount of other ingredients, dosage form, etc., and is not limited to these, but is typically 0.1-5% by mass, 0.2-4% by mass, 0.3-3% by mass, or 0.4-2% by mass relative to the total amount (100% by mass) of the rash-inhibiting composition.

[0046] (Thickening agent) Examples of thickening agents include gums (gellan gum, xanthan gum, sclerotium gum, locust bean gum, biosaccharide gum, tamarind gum, quince seed gum, gum arabic, tara gum, guar gum, galactan, gum arabic, tragacanth gum, etc.), carrageenan, curdlan, succinoglucan, heparinoids, alginates (alginic acid, sodium alginate, propylene glycol alginate, etc.), agar (including agarose), gelatin, pectin, pullulan, mannan, vinyl-based thickeners (polyvinyl alcohol, polyvinylpyrrolidone, polyvinyl methyl ether, carboxyvinyl polymer, etc.), and cellulose-based thickeners (methylcellulose, ethylcellulose). Examples include lurose, hydroxyethylcellulose, hydroxymethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, carboxymethylcellulose, carboxyethylcellulose, hydrophobized hydroxypropylmethylcellulose, etc., dextran, dextrin, alkyl acrylate methacrylate copolymer, sodium polyacrylate, bentonite, dextrin fatty acid ester, dimethyldistearylammonium hectorite, polyethylene glycol, macrogol, (hydroxyethyl acrylate / sodium acryloyldimethyltaurate) copolymer, (ammonium acryloyldimethyltaurate / vinylpyrrolidone) copolymer, etc. The total amount of the thickening agent can be set appropriately depending on the type and amount of other components, dosage form, etc., and is not limited to any particular amount, but it may be, for example, 0.001 to 5% by mass, 0.01 to 3% by mass, or 0.05 to 1% by mass, relative to the total amount (100% by mass) of the rash-inhibiting composition.

[0047] (Preservative) Preservatives include benzoic acid, benzoates, alkyldiaminoethylglycine hydrochloride, photosensitizer, chlorcresol, chlorobutanol, salicylic acid, salicylates, sorbic acid and its salts, dehydroacetic acid and its salts, trichlorohydroxydiphenyl ether (also known as triclosan), parahydroxybenzoic acid esters and their sodium salts (methyl parahydroxybenzoate, ethyl parahydroxybenzoate, etc.), phenoxyethanol, sodium lauryldiaminoethylglycine, resorcinol, zinc-ammonia-silver complex substituted zeolite, pantothenyl ethyl benzoate, isopropylmethylphenol, cetylpyridinium chloride, benzalkonium chloride, benzethonium chloride, chlorhexidine hydrochloride, orthophenylphenol, orthophenylphenol Examples include sodium chloroisothiazolinone, silver-copper zeolite, chlorhexidine gluconate, cresol, chloramine T, chloroxylenol, chlorphenesin, chlorhexidine, 1,3-dimethylol-5,5-dimethylhydantoin, alkylisoquinolinium bromide, thianthol, thymol, trichlorocarbanilide, parachlorophenol, halocarban, hinokitiol, zinc pyrithione, piroctone olamine, iodide propynyl butylcarbamate, polyaminopropyl biguanide, methylisothiazolinone, methylchloroisothiazolinone / methylisothiazolinone solution, N,N"-methylenebis[N'-(3-hydroxymethyl-2,5-dioxo-4-imidazolidinyl)urea], and iodide-paradimethylaminostyrylheptylmethylthiazolium.

[0048] In preferred embodiments of this rash-inhibiting composition, it is preferable that the composition be substantially free of preservatives from the viewpoint of suppressing irritation to the skin and mucous membranes. "Substantially free of preservatives" means that the total amount of preservatives is 0.5% by mass or less of the total amount (100% by mass) of this rash-inhibiting composition, preferably 0.1% by mass or less, more preferably 0.01% by mass, even more preferably 0.001% by mass or less, even more preferably 0.0001% by mass, and most preferably 0% by mass.

[0049] (pH adjuster) pH adjusters are not particularly limited, but examples include inorganic bases such as potassium hydroxide, sodium hydroxide, and sodium carbonate; organic bases such as triethanolamine, diisopropanolamine, and triisopropanolamine; inorganic acids such as hydrochloric acid and sulfuric acid; and organic acids such as lactic acid, sodium lactate, citric acid, sodium citrate, succinic acid, and sodium succinate. These can be used alone or in combination of two or more. The total content of the pH adjuster can be appropriately set depending on the type and amount of other components, dosage form, etc., and is not limited, but is, for example, 0.001 to 2.5% by mass, preferably 0.005 to 2% by mass, and more preferably 0.01 to 1% by mass, relative to the total amount (100% by mass) of the rash-inhibiting composition.

[0050] (Chelating agent) Examples of chelating agents include EDTA-2 sodium salt, EDTA-calcium-2 sodium salt, gluconolactone, and caprylhydroxamic acid. The total content of the chelating agent can be appropriately set depending on the type and amount of other components, dosage form, etc., and is not limited to any particular amount, but is, for example, 0.001 to 2.5% by mass, preferably 0.005 to 2% by mass, and more preferably 0.01 to 1% by mass, relative to the total amount (100% by mass) of the rash-inhibiting composition.

[0051] (Coloring agent) Examples of colorants include inorganic pigments and natural dyes. The total content of the coloring agent can be appropriately set depending on the type and amount of other components, dosage form, etc., and is not limited, but is, for example, 0.001 to 1% by mass, preferably 0.005 to 0.1% by mass, and more preferably 0.01 to 0.05% by mass, relative to the total amount (100% by mass) of the rash-suppressing composition.

[0052] This rash-suppressing composition may contain other active ingredients as long as they do not impair the effects of the present invention. Specific examples of active ingredients, but not limited to those listed below, include moisturizing ingredients, scrubbing agents, blood circulation promoters, astringent ingredients, UV-absorbing ingredients, anti-inflammatory agents, vitamins, peptides or their derivatives, amino acids or their derivatives, and cell-activating ingredients. These can be used alone or in combination of two or more.

[0053] (moisturizing ingredient) Examples of moisturizing ingredients include polyhydric alcohols such as 1,3-butylene glycol, 1,3-propanediol, propylene glycol, pentanediol, glycerin, diglycerin, sorbitol, and polyethylene glycol; chondroitin sulfate or its salts (sodium chondroitin sulfate, potassium chondroitin sulfate, sodium dermatan sulfate, potassium dermatan sulfate, etc.); PPG-17 buteth-17, PPG-25 sorbitol, polyoxyalkylene alkyl glucoside, PEG / PPG / polybutylene glycol-8 / 5 / 3 glycerin, and polyoxyalkylene diglyceryl. Examples include lucilene oxide; glycosyl trehalose, trehalose; ceramide, glucosylceramide, cholesterol, phytosterol, cholesterol derivatives, phytosterol derivatives; 2-methacryloyloxyphosphorylcholine-butyl methacrylate copolymer solution, polymethacryloyloxyethyl phosphorylcholine and other 2-methacryloyloxyphosphorylcholine-containing polymers; NMF-derived components such as lactic acid, sodium lactate, sodium pyrrolidone carboxylate, and urea; collagen, elastin, keratin, chitin, chitosan and their hydrolysates; and hydroxyethyl urea. The total content of moisturizing ingredients can be appropriately set according to the type and amount of other ingredients, dosage form, etc., and is not limited to these, but is, for example, 0.001 to 60% by mass, 0.01 to 50% by mass, preferably 0.03 to 40% by mass, and more preferably 0.05 to 30% by mass, relative to the total amount (100% by mass) of the rash-suppressing composition.

[0054] (Scrubbing agent) Examples of scrubbing agents include apricot kernel powder, almond shell powder, sodium chloride granules, olive kernel powder, candelilla wax, walnut shell powder, cherry kernel powder, coral powder, charcoal powder (paulownia charcoal, binchotan charcoal, bamboo charcoal, cypress charcoal, coconut shell charcoal and activated charcoals thereof, as well as medicinal charcoals thereof), hazelnut shell powder, and polyethylene powder. The total amount of the scrubbing agent can be set appropriately depending on the type and amount of other ingredients, dosage form, etc., and is not limited to this, but is, for example, 0.01 to 15% by mass, preferably 0.05 to 10% by mass, and more preferably 0.1 to 5% by mass, relative to the total amount (100% by mass) of the rash-inhibiting composition.

[0055] (Blood circulation promoter) Examples of blood circulation-promoting agents include acetylcholine, ichthammol, caffeine, capsaicin, cantharis tincture, γ-oryzanol, gingerol tincture, cepharanthine, swertia japonica extract, tannic acid, capsicum tincture, trazoline, tocopherol nicotinate, and benzyl nicotinate. The total amount of the blood circulation promoter can be appropriately set according to the type and amount of other components, dosage form, etc., and is not limited, but is, for example, 0.001 to 5% by mass, preferably 0.005 to 3% by mass, and more preferably 0.01 to 1% by mass, relative to the total amount (100% by mass) of the rash-suppressing composition.

[0056] (Astringent ingredients) Examples of astringent components include zinc sulfate, aluminum hydroxyaluminum, aluminum chloride, zinc sulfocarbonate, and tannic acid. The total content of the astringent component can be appropriately set depending on the type and amount of other components, dosage form, etc., and is not limited to this, but is, for example, 0.001 to 20% by mass, preferably 0.01 to 15% by mass, and more preferably 0.1 to 10% by mass, relative to the total amount (100% by mass) of the rash-inhibiting composition.

[0057] (UV absorbing ingredients) Examples of UV-absorbing ingredients include octyl triazone, diethylamino hydroxybenzoyl hexyl benzoate, octyl dimethoxybenzylidene dioxoimidazolidine propionate, 2-ethylhexyl paramethoxycinnamate, t-butyl methoxydibenzoylmethane, phenylbenzimidazole sulfonic acid, octyl methoxycinnamate, and ethylhexyl methoxycinnamate. The total content of the ultraviolet-absorbing component can be appropriately set depending on the type and amount of other components, dosage form, etc., and is not limited, but is, for example, 1 to 30% by mass, preferably 3 to 25% by mass, and more preferably 5 to 20% by mass, relative to the total amount (100% by mass) of the rash-suppressing composition.

[0058] (Anti-inflammatory drugs) Examples of anti-inflammatory agents include non-steroidal anti-inflammatory drugs (NSAIDs) and steroidal anti-inflammatory drugs. Specifically, these include glycyrrhizic acid, glycyrrhetinic acid, stearyl glycyrrhetinate, allantoin, epsilon-aminocaproic acid, salicylic acid, methyl salicylate, glycol salicylate, indomethacin, felbinac, ibuprofen, ibuprofen piconol, ketoprofen, bufexamac, butyl flufenamate, bendazac, piroxicam, suprofen, azulene, guaiazulene, dexamethasone acetate valerate, dexamethasone, prednisolone acetate valerate (prednisolone valerate acetate), prednisolone acetate, prednisolone, hydrocortisone acetate, hydrocortisone, ufenamate, bufexamac, and their salts. The total content of the anti-inflammatory agent can be appropriately set depending on the type and amount of other components, dosage form, etc., and is not limited to this, but is, for example, 0.001 to 5% by mass, preferably 0.005 to 4.5% by mass, and more preferably 0.01 to 3% by mass, relative to the total amount (100% by mass) of the rash-suppressing composition.

[0059] (Vitamins) Vitamins include vitamin E derivatives such as dl-α-tocopherol, dl-α-tocopherol succinate, and dl-α-tocopherol calcium succinate; vitamin B2 derivatives such as riboflavin, flavin mononucleotide, flavin adenine dinucleotide, riboflavin butyrate, riboflavin tetrabutyrate, riboflavin 5'-phosphate sodium, and riboflavin tetranicotinate; and dl-α-tocopherol nicotinate, benzyl nicotinate, methyl nicotinate, β-butoxyethyl nicotinate, and 1 nicotinate. Nicotinic acids such as -(4-methylphenyl)ethyl; vitamin C compounds such as ascorbigen-A, ascorbic acid stearate, ascorbic acid palmitate, and L-ascorbyl dipalmitate; vitamin D compounds such as methyl hesperidin, ergocalciferol, and cholecalciferol; vitamin K compounds such as phylloquinone and farnoquinone; γ-oryzanol, dibenzoylthiamine, dibenzoylthiamine hydrochloride; thiamine hydrochloride, thiamine cetyl hydrochloride, thiamine thiocyanate, thiamine lauryl hydrochloride, and thiamine nitrate. Vitamin B1s such as thiamine salt, thiamine monophosphate, thiamine lysine salt, thiamine triphosphate, thiamine monophosphate phosphate, thiamine monophosphate, thiamine diphosphate, thiamine diphosphate hydrochloride, thiamine triphosphate, and thiamine triphosphate monophosphate; Vitamin B6s such as pyridoxine hydrochloride, pyridoxine acetate, pyridoxal hydrochloride, pyridoxal 5'-phosphate, and pyridoxamine hydrochloride; Vitamin B12s such as cyanocobalamin, hydroxocobalamin, and deoxyadenosylcobalamin. Folic acid derivatives such as folic acid and pteroylglutamic acid; nicotinic acid derivatives such as nicotinic acid and nicotinamide; pantothenic acid derivatives such as pantothenic acid, calcium pantothenate, pantothenyl alcohol (panthenol), D-panthesine, D-pantethine, coenzyme A, and pantothenyl ethyl ether; biotin derivatives such as biotin and biotisine; vitamin C derivatives such as ascorbic acid, sodium ascorbate, dehydroascorbic acid, sodium ascorbate phosphate, and magnesium ascorbate phosphate;Examples include vitamin-like factors such as carnitine, ferulic acid, alpha-lipoic acid, and orotic acid. The total vitamin content can be appropriately set depending on the type and amount of other components, dosage form, etc., and is not limited to any one value, but is, for example, 0.001 to 25% by mass, preferably 0.01 to 20% by mass, and more preferably 0.05 to 15% by mass, relative to the total amount (100% by mass) of the rash-inhibiting composition.

[0060] (Peptides or their derivatives) Examples of peptides or their derivatives include keratin-degrading peptides, hydrolyzed keratin, collagen, fish-derived collagen, atelocollagen, gelatin, elastin, elastin-degrading peptides, collagen-degrading peptides, hydrolyzed collagen, hydroxypropylammonium chloride hydrolyzed collagen, elastin-degrading peptides, conchiolin-degrading peptides, hydrolyzed conchiolin, silk protein-degrading peptides, hydrolyzed silk, sodium lauroyl hydrolyzed silk, soy protein-degrading peptides, hydrolyzed soy protein, wheat protein, wheat protein-degrading peptides, hydrolyzed wheat protein, casein-degrading peptides, and acylated peptides (such as palmitoyl oligopeptides, palmitoyl pentapeptides, and palmitoyl tetrapeptides). The total content of peptides or their derivatives can be appropriately set depending on the type and amount of other components, dosage form, etc., and is not limited, but is, for example, 0.001 to 5% by mass, preferably 0.01 to 3% by mass, and more preferably 0.05 to 1% by mass, relative to the total amount (100% by mass) of the rash-inhibiting composition.

[0061] (Amino acids or their derivatives) Examples of amino acids or their derivatives include betaine (trimethylglycine), proline, hydroxyproline, arginine, lysine, serine, glycine, alanine, phenylalanine, β-alanine, threonine, glutamic acid, glutamine, asparagine, aspartic acid, cysteine, cystine, methionine, leucine, isoleucine, valine, histidine, taurine, γ-aminobutyric acid, γ-amino-β-hydroxybutyric acid, carnitine, carnosine, and creatine. The total content of amino acids or their derivatives can be appropriately set depending on the type and amount of other components, dosage form, etc., and is not limited, but is, for example, 0.001 to 5% by mass, preferably 0.01 to 3% by mass, and more preferably 0.05 to 1% by mass, relative to the total amount (100% by mass) of the rash-inhibiting composition.

[0062] (Cell-activating component) Examples of cell-activating components include α-hydroxy acids such as glycolic acid and lactic acid, tannins, flavonoids, and saponins. The total content of the cell-activating component can be appropriately set depending on the type and amount of other components, dosage form, etc., and is not limited to this, but is, for example, 0.001 to 5% by mass, preferably 0.01 to 3% by mass, and more preferably 0.05 to 1% by mass, relative to the total amount (100% by mass) of the rash-inhibiting composition.

[0063] [pH] The pH of this rash-inhibiting composition can be set appropriately depending on the dosage form and other factors, and is not limited thereto, but for example, pH 3.5 to 11.0 is preferred, more preferably pH 4.0 to 9.0, even more preferably pH 4.0 to 7.5, and even more preferably pH 4.5 to 7.0. The pH is measured at room temperature (25°C) using a pH meter (for example, pH METER F-52 (manufactured by HORIBA)).

[0064] When this rash-inhibiting composition is used on delicate areas, the pH is not limited, but for example, pH 3.5 to 8.0 is preferred, more preferably pH 4.0 to 7.0, even more preferably pH 4.0 to 6.5, and even more preferably 4.5 to 5.5.

[0065] [viscosity] The viscosity (at 25°C) of this rash-inhibiting composition can be appropriately set depending on the dosage form, etc. For example, it is 0.1 to 1,000,000 mPa·s, preferably 1 to 500,000 mPa·s, more preferably 10 to 100,000 mPa·s, even more preferably 100 to 50,000 mPa·s, even more preferably 100 to 30,000 mPa·s, even more preferably 100 to 10,000 mPa, and most preferably 100 to 5,000 mPa·s.

[0066] The viscosity (at 25°C) is measured in accordance with the viscosity measurement method described in the General Test Methods of the 18th Revised Japanese Pharmacopoeia. If the value exceeds 100 mPa, it refers to the viscosity measured using a single-cylinder rotational viscometer (Brookfield type viscometer). Specifically, it refers to the value measured using, for example, a TV-10M (manufactured by Toki Sangyo Co., Ltd.). The selection of conditions such as rotor and rotation speed is in accordance with the instruction manual for this instrument, and the viscosity at 25°C is measured. More specifically, the viscosity at 25°C is measured using an M4 rotor, under conditions of a rotation speed of 0.3 rpm and a measurement time of 180 seconds.

[0067] The following is a description of a single-cylinder rotational viscometer. A single-cylinder rotational viscometer is a viscometer that measures the torque when a cylinder in a liquid is rotated at a constant angular velocity. The viscosity η of the liquid is calculated by the following formula after experimentally determining the apparatus constant KB using a viscometer calibration standard solution. η = KB × T / ω η: Viscosity of liquid (mPa·s) KB: Equipment constant (rad / cm 3 ) ω: Angular velocity (rad / s) T: Torque acting on the cylindrical surface (10 -7 N·m)

[0068] Furthermore, values ​​below 100 mPa refer to viscosity measured using a cone-plate type rotational viscometer. Specifically, this refers to values ​​measured using, for example, the TV-20 (manufactured by Toki Sangyo Co., Ltd.), and the selection of conditions such as rotor and rotation speed shall conform to the instruction manual of this instrument, and the viscosity shall be measured at 25°C. More specifically, a cone rotor (1°34' × R24) shall be used, and the viscosity shall be measured at 25°C under the conditions of a rotation speed of 50 rpm and 3 minutes after the start of measurement.

[0069] [Manufacturing method] This rash-inhibiting composition can be manufactured by known methods. For example, it can be manufactured by mixing each component in accordance with or in accordance with the 18th edition of the Japanese Pharmacopoeia.

[0070] [Formulation form, etc.] This rash-inhibiting composition is provided in any form that can be widely used as a cosmetic, quasi-drug, pharmaceutical, etc. The formulation form of this rash-inhibiting composition is not particularly limited and includes liquids, oils, suspensions, emulsions, creams, emulsion ointments, ointments, gels, liniments, lotions, foams, sprays, aerosols, mists, pump foams, sheets impregnated with the drug solution (such as nonwoven fabric), sticks, powders, and the like.

[0071] This rash-inhibiting composition can be suitably used in external skin compositions such as lotions, mists, moisturizing oils, emulsions, creams, gels, serums, sunscreens, antiperspirants, and powders; skin cleansing compositions such as body soaps (also called body shampoos), hand soaps, facial cleansers, makeup removers, shampoos, dry shampoos, and rinse-in shampoos; and vaginal cleansers. In particular, it is suitable as an external composition and a cleansing composition for delicate areas.

[0072] [container] This rash-inhibiting composition can be filled into a container appropriately selected according to its intended use and application. Examples of such containers include bottles, tubes, jars, mist dispensers, sprays, aerosols, dispensers, pump-formers, pouches, and spout pouches. Examples of materials that make up the container include polyethylene terephthalate, polypropylene, polyethylene (HDPE, LDPE, LLDPE, etc.), ABS resin, ethylene vinyl alcohol resin, polystyrene, glass, and metals (aluminum, etc.), and mixtures thereof. Furthermore, containers molded from these materials may be treated with various coatings on the surface, for example, taking into consideration strength, flexibility, weather resistance, or stability of the components. Containers can also be formed by laminating films molded from the aforementioned materials.

[0073] [Application area] The areas to which this rash-inhibiting composition is applied are not particularly limited, and examples include one or more selected from the group consisting of the face (including around the eyes and mouth), neck, chest, back, arms, elbows, hands, armpits, abdomen, genitals, buttocks, anal area, legs, fingers, toes, and soles of the feet. Particularly preferred are one or more selected from the group consisting of the back, upper arms, armpits, abdomen, genitals, buttocks, anal area, legs, toes, and soles of the feet. In particular, from the viewpoint of being susceptible to physical and / or chemical irritation from contact with clothing, urine, sweat, feces, urinary care products, etc., one or more selected from the group consisting of the neck, chest, back, arms, elbows, abdomen, genitals, buttocks, anal area, groin, waist, legs, toes, and soles of the feet. In particular, this rash-inhibiting composition is preferable to apply to delicate areas because it is excellent at suppressing the activity of proteases and lipases derived from commensal bacteria in those areas. For example, in women, rashes caused by menstrual blood, sweat, and urine during menstruation tend to worsen, and in men, rashes caused by sweat and urine tend to worsen. Therefore, it is preferable to apply it to delicate areas where absorbent items such as sanitary napkins and diapers, and underwear, come into direct contact with the body. More specifically, this rash-inhibiting composition is preferably applied to one or more delicate areas selected from the group consisting of the genitals, buttocks, anal area, groin, and lower back.

[0074] [Applicable persons] The target population for this rash-suppressing composition is not particularly limited, but it can include individuals prone to developing rashes or those who have developed symptoms of a rash. For example, it can be applied to young to middle-aged women (approximately 15 to under 45 years old) who are prone to developing rashes from contact with sanitary napkins, and middle-aged (approximately 45 to under 55 years old) and elderly (approximately 55 years and older) women who are prone to developing rashes from urine, etc. In particular, women after menopause have a high frequency of urinary incontinence, and rashes may worsen due to the mixing of vaginal discharge, irritation from underwear or absorbent materials, etc. Because the present invention has excellent preventive and therapeutic effects on rashes, it is particularly useful for these target populations. Furthermore, the target population for this rash-suppressing composition can also include, for example, newborns, infants, and toddlers who are prone to diaper rash.

[0075] [Purpose, etc.] This rash-inhibiting composition is used to suppress rashes. Specifically, it is used for the prevention, treatment, and / or improvement of rash symptoms, particularly for the prevention, treatment, and / or improvement of rashes in delicate areas. Furthermore, this rash-suppressing composition is used for purposes such as normalizing the skin, normalizing the skin environment, improving the skin environment, regulating the skin environment, regulating the skin condition, making the skin environment comfortable, regulating the skin condition, regulating the skin barrier function, suppressing itching, and suppressing rashes. It is also suitable for application to delicate areas, and can be used in particular to normalize the skin of delicate areas, normalize the skin environment, improve the skin environment, regulating the skin environment, regulating the skin condition, making the skin environment comfortable, regulating the barrier function, making the delicate area environment comfortable, suppressing itching in delicate areas, suppressing rashes in delicate areas, and reducing unpleasant odors in delicate areas.

[0076] Furthermore, this rash-inhibiting composition can be used for the prevention, treatment, and / or improvement of symptoms of contact dermatitis, specifically, symptoms such as erythema, papules, edema, vesicles, and blisters, which may be accompanied by itching.

[0077] <Skin irritation inhibitors, enzyme activity inhibitors> Embodiments of the present invention include a rash inhibitor containing one or more selected from the group consisting of low molecular weight hyaluronic acid, derivatives of low molecular weight hyaluronic acid, and salts thereof as an active ingredient. Another embodiment of the present invention includes an enzyme activity inhibitor containing one or more selected from the group consisting of low molecular weight hyaluronic acid, derivatives of low molecular weight hyaluronic acid, and salts thereof as an active ingredient. Furthermore, embodiments of the present invention include external compositions (particularly skin cleansing compositions) containing a rash inhibitor and / or enzyme activity inhibitor, wherein one or more selected from the group consisting of low molecular weight hyaluronic acid, derivatives of low molecular weight hyaluronic acid, and salts thereof are used as active ingredients.

[0078] <Use of low-molecular-weight hyaluronic acid, etc.> Embodiments of the present invention include the use of one or more substances selected from the group consisting of low molecular weight hyaluronic acid, derivatives of low molecular weight hyaluronic acid, and salts thereof, for the production of a rash inhibitor and / or enzyme activity inhibitor. Embodiments of the present invention include the use of one or more substances selected from the group consisting of low molecular weight hyaluronic acid, derivatives of low molecular weight hyaluronic acid, and salts thereof, for producing a composition for suppressing skin irritation.

[0079] <Methods for imparting a rash-inhibiting effect, methods for imparting an enzyme activity-inhibiting effect> Embodiments of the present invention include a method for imparting a skin topical composition with an effect of suppressing rashes, which involves incorporating one or more substances selected from the group consisting of low molecular weight hyaluronic acid, derivatives of low molecular weight hyaluronic acid, and salts thereof into the skin topical composition. Furthermore, an embodiment of the present invention includes a method for imparting to a topical skin composition the effect of suppressing the activity of enzymes derived from commensal bacteria, which involves incorporating one or more substances selected from the group consisting of low molecular weight hyaluronic acid, derivatives of low molecular weight hyaluronic acid, and salts thereof into the topical skin composition.

[0080] <Methods to suppress skin irritation, methods to suppress enzyme activity> Embodiments of the present invention include a method for suppressing skin irritation by applying a composition containing one or more selected from the group consisting of low molecular weight hyaluronic acid, derivatives of low molecular weight hyaluronic acid, and salts thereof to the skin. Furthermore, an embodiment of the present invention is a method for inhibiting the activity of enzymes derived from commensal bacteria by applying a composition containing one or more selected from the group consisting of low molecular weight hyaluronic acid, derivatives of low molecular weight hyaluronic acid, and salts thereof to the skin.

[0081] Furthermore, the above method is preferably a non-therapeutic method. A "non-therapeutic method" is a method that does not involve surgery, treatment, or diagnosis of a human being, and specifically, a method that does not involve surgery, treatment, or diagnosis performed on a human being by a physician or a person under the direction of a physician. [Examples]

[0082] The present invention will be described in detail below based on examples, but the present invention is not limited to these examples. The units of content shown in the examples and formulation examples are in mass%.

[0083] <Enzyme activity evaluation test> (Preparation of controls) Disodium hydrogen phosphate and sodium dihydrogen phosphate dihydrate were dissolved in purified water to prepare a phosphate buffer with a pH of 6.2. Protease (Protease CL-15, manufactured by Nagase ChemteX, serine protease) was added to the phosphate buffer to a concentration of 0.1% by mass, and then the mixture was stirred and dissolved to prepare a test sample for the control.

[0084] (Preparation of the examples) Hyalooligo (hydrolyzed hyaluronic acid, weight-average molecular weight 10,000 or less, manufactured by Kewpie Corporation, registered trademark) was added to the control to a concentration of 2% by mass, then stirred and dissolved to prepare the test sample according to Example 1.

[0085] (Preparation of comparative examples) To the control, one of the following was added in a quantity of 2% by mass: Pentavitin (isomerized sugar, DSM, registered trademark), fermented hyaluronic acid solution (lactic acid bacteria / hyaluronic acid ferment solution) (obtained by fermenting hyaluronic acid with lactic acid bacteria as a substrate and then filtering), xylitol, or BIOECOLIA (α-glucan oligosaccharide, Solabia Group, registered trademark). The mixture was then stirred and dissolved to prepare test samples for Comparative Examples 1 to 4.

[0086] 1 ml of the test sample was filled into a 15 mL glass vial, and the reaction time between the sample solution and the casein solution was changed from 10 minutes to 30 minutes according to the "Protease Titer Test Method, Method 1" of the Quasi-Drug Raw Material Standards, and the results were measured. The enzyme activity of the examples and comparative examples was determined with the control enzyme activity (U / g) set to 100. The results are shown in Table 1 and Figure 1.

[0087] In the unit "U / g" mentioned above, "U (unit)" indicates the activity of the enzyme. One protease unit is defined as the amount of enzyme (1 micromol / min) that can convert 1 micromol (μmol) of substrate per minute under optimal conditions (at a temperature of 30°C and the acidity at which the chemical reaction proceeds most effectively).

[0088] [Table 1]

[0089] As shown in Table 1 and Figure 1, the enzyme activity in Comparative Examples 1-4, with the addition of isomerized sugar, lactic acid bacteria / hyaluronic acid ferment filtrate, xylitol, and α-glucan oligosaccharide, was confirmed to be equivalent to that of the control. No inhibitory effect on enzyme activity was observed with these components.

[0090] On the other hand, the enzyme activity of the sample with hydrolyzed hyaluronic acid (weight-average molecular weight less than 10,000) added in Example 1 was surprisingly significantly reduced compared to the control. This revealed that hydrolyzed hyaluronic acid has an inhibitory effect on enzyme activity, and that this effect is remarkable.

[0091] These results suggest that low-molecular-weight hyaluronic acid can suppress skin irritation due to its excellent enzyme activity inhibitory effect.

[0092] Furthermore, the enzyme activity inhibitory effect according to the embodiment of the present invention is not limited to the excellent inhibitory effect of Example 1. For example, when the control enzyme activity is set to 100, it is sufficient if it is 70 or less, preferably 50 or less, more preferably 30 or less, even more preferably 10 or less, particularly preferably 5 or less, and even more preferably 1 or less.

[0093] Examples of formulations of the present invention are shown below.

[0094] <Example of formulation 1: Body soap (gel type) (pH 6.0 (undiluted solution)> Glycerin 5.0% by mass BG 3.0% by mass Polyglyceryl-10 Laurate 3.0% by mass Decyl glucoside 3.0% by mass Sodium cocoyl glutamate 1.5% by mass Lauryl hydroxysultaine 2.0% by mass Viscosity modifier 2.0% by mass Hydrolyzed hyaluronic acid 0.1% by mass Dipotassium glycyrrhizate 0.1% by mass EDTA-2Na 0.1% by mass pH adjuster (appropriate amount) Purified water residue

[0095] <Example of formulation 2: Body soap (foaming type) (pH 5.8 (undiluted solution))> Propylene glycol 5.0% by mass Glycerin 2.0% by mass Polyglyceryl-10 Laurate 3.0% by mass Sodium Cocoyl Methyl Taurate 3.0% by mass Sodium lauroyl glutamate 3.0% by mass Sodium lauroamphoacetate 3.0% by mass Glyceryl caprate 1.0% by mass Hydrolyzed hyaluronic acid 1.0% by mass Dipotassium glycyrrhizate 0.1% by mass EDTA-2Na 0.1% by mass pH adjuster (appropriate amount) Purified water residue

[0096] <Example of formulation 3: Lotion (pH 5.0 (undiluted solution))> Tocopherol acetate 0.1% by mass Isostearyl alcohol 3.0% by mass Triethylhexanoin 1.0% by mass Sorbitan oleate 0.5% by mass PEG-30 Glyceryl Isostearate 1.0% by mass PEG-40 Glyceryl Isostearate 0.8% by mass PCA Glycereth-25 Isostearate 0.6% by mass BG 8.0% by mass Glycerin 4.0% by mass Hydrolyzed hyaluronic acid 0.5% by mass Dipotassium glycyrrhizate 0.1% by mass EDTA-2Na 0.1% by mass pH adjuster (appropriate amount) Purified water residue

Claims

1. A composition for suppressing skin irritation, characterized by containing one or more selected from the group consisting of low molecular weight hyaluronic acid, derivatives of low molecular weight hyaluronic acid, and salts thereof.

2. The rash-inhibiting composition according to claim 1, which inhibits the activity of hydrolytic enzymes.

3. The rash-inhibiting composition according to claim 2, wherein the hydrolytic enzyme is one or more selected from the group consisting of proteases, lipases, and ureases.

4. The rash-inhibiting composition according to claim 2 or 3, wherein the hydrolytic enzyme is a hydrolytic enzyme derived from a microorganism.

5. The rash-suppressing composition according to claim 1 or 2, wherein the low molecular weight hyaluronic acid is hydrolyzed hyaluronic acid.

6. A rash-suppressing composition according to claim 1 or 2, for use on delicate areas.

7. A method for suppressing skin irritation by applying a composition containing one or more selected from the group consisting of low molecular weight hyaluronic acid, derivatives of low molecular weight hyaluronic acid, and salts thereof to the skin.

Images